Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
83.77
+0.72 (+0.87%)
Streaming Delayed Price
Updated: 12:56 PM EDT, Sep 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer
February 17, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Choroidal Neovascularization Market Share Size Trends Overview Analysis 2022-2029
February 16, 2023
Global Choroidal Neovascularization Market to Witness Huge Growth by Key Players: Bausch Health Companies Inc, Bayer AG, Gilead Sciences Inc, F.Hoffmann –La Roche AG,MaaT Pharma Novartis AG, Pfizer...
Via
SBWire
Cholecystitis Treatment Market Demand Trends Outlook Overview Analysis 2022-2029
February 16, 2023
Global Cholecystitis Treatment Market to Witness Huge Growth by Key Players: Boston Scientific, Dornier MedTech GmbH, Fresenius Kabi, AuroMedics Pharmaceuticals, Sanofi, SUNUET Pharmaceuticals, Hetero...
Via
SBWire
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
February 14, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Mount Gilead, OH Author Publishes Children's Book
February 02, 2023
This Kids Book Features the Cutest Baby Elephant You Will Ever See!
Via
PR Leap
Mount Gilead, NC Author Publishes Children's Book
January 12, 2023
So Excited, She Runs To Solve The Mystery Of What She Is Smelling.
Via
PR Leap
Europe Liver Cancer Therapeutics Market to Reach at High CAGR of 8.95% by 2023-2030
February 09, 2023
The Europe liver cancer therapeutics size was valued at US$ 384 million in 2022 and is estimated to reach US$ 627 million by 2030, growing at a CAGR of 8.95% during the forecast period (2023-2030)
Via
SBWire
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
February 09, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Europe Liver Cancer Therapeutics Market Is at the Cusp of Crossing CAGR of 8.95% N 2023-2030
February 08, 2023
Global Europe Liver Cancer Therapeutics Market to Witness Huge Growth by Key Players: Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead...
Via
SBWire
Topics
Death
Exposures
Death
Is Biotech Immunocore About To Make A 25% Price Move?
February 07, 2023
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.
Via
MarketBeat
Topics
ETFs
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
February 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend
February 02, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results
February 02, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Liposome Drug Delivery Market 2023 in-Depth Analysis, Growth, Size, Future Prospect, Regional Development and Global Outlook 2029
February 02, 2023
Liposome Drug Delivery Market Size, Share and Forecast 2023-2029 Key Players are – Ipsen Pharma, Celsion Corp, Gilead Sciences, Astellas Pharma, Johnson & Johnson, Luye Pharma Group, Novartis AG
Via
SBWire
Exposures
COVID-19
Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer
February 01, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
January 30, 2023
From
Gilead Sciences, Inc. and Arcellx, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
January 27, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Mergers and Acquisitions in 2023 Off To A Strong Start
January 26, 2023
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.
Via
MarketBeat
Exposures
Product Safety
Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023
January 19, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Cell and Gene Therapy Market Size, Share, Industry Analysis, Growth Estimates, Trends, Demand and Forecast 2022-2028
January 13, 2023
Global Cell and Gene Therapy Market will worth USD 21,508 million by 2028-end at a CAGR of 28.2% from 2022 to 2028 according to Intelligence Market Report
Via
SBWire
European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer
January 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
January 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
December 27, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conference
December 23, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma
December 22, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV
December 22, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
December 20, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
December 19, 2022
From
Arcus Biosciences
Via
Business Wire
Harpoon Therapeutics Remains Volatile After Promising News
December 14, 2022
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%.
Via
MarketBeat
Gilead Sciences Again Named to Dow Jones Sustainability World Index
December 12, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.